Literature DB >> 16966400

Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae.

Andrew S Chau1, Guodong Chen, Paul M McNicholas, Paul A Mann.   

Abstract

Posaconazole and itraconazole were more potent inhibitors of ergosterol synthesis, in both intact cells and cell extracts from Absidia corymbifera and Rhizopus oryzae, than voriconazole and fluconazole. Similarly, expression of CYP51 from R. oryzae in Saccharomyces cerevisiae significantly increased resistance to fluconazole and voriconazole but not to posaconazole and itraconazole.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16966400      PMCID： PMC1635193          DOI： 10.1128/AAC.00747-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Posaconazole as salvage therapy for zygomycosis.

Authors:  R N Greenberg; K Mullane; J-A H van Burik; I Raad; M J Abzug; G Anstead; R Herbrecht; A Langston; K A Marr; G Schiller; M Schuster; J R Wingard; C E Gonzalez; S G Revankar; G Corcoran; R J Kryscio; R Hare
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 2.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases.

Authors:  Maureen M Roden; Theoklis E Zaoutis; Wendy L Buchanan; Tena A Knudsen; Tatyana A Sarkisova; Robert L Schaufele; Michael Sein; Tin Sein; Christine C Chiou; Jaclyn H Chu; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2005-07-29       Impact factor: 9.079

3.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.

Authors:  Dimitrios P Kontoyiannis; Michail S Lionakis; Russell E Lewis; Georgios Chamilos; Mimi Healy; Cheryl Perego; Amar Safdar; Hagop Kantarjian; Richard Champlin; Thomas J Walsh; Issam I Raad
Journal:  J Infect Dis       Date:  2005-03-16       Impact factor: 5.226

4.  Interaction of microsomal cytochrome P-450 isolated from Aspergillus fumigatus with fluconazole and itraconazole.

Authors:  S A Ballard; S L Kelly; S W Ellis; P F Troke
Journal:  J Med Vet Mycol       Date:  1990

Review 5.  Posaconazole: a broad-spectrum triazole antifungal.

Authors:  Harrys A Torres; Ray Y Hachem; Roy F Chemaly; Dimitrios P Kontoyiannis; Issam I Raad
Journal:  Lancet Infect Dis       Date:  2005-12       Impact factor: 25.071

6.  Effects of Y132H and F145L substitutions on the activity, azole resistance and spectral properties of Candida albicans sterol 14-demethylase P450 (CYP51): a live example showing the selection of altered P450 through interaction with environmental compounds.

Authors:  Makiko Kudo; Miwa Ohi; Yuri Aoyama; Yuko Nitahara; Sung-Kee Chung; Yuzo Yoshida
Journal:  J Biochem       Date:  2005-05       Impact factor: 3.387

7.  Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds.

Authors:  Hanan K Munayyer; Paul A Mann; Andrew S Chau; Taisa Yarosh-Tomaine; Jonathan R Greene; Roberta S Hare; Larry Heimark; Robert E Palermo; David Loebenberg; Paul M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 8.  Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections.

Authors:  R Herbrecht
Journal:  Int J Clin Pract       Date:  2004-06       Impact factor: 2.503

9.  Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.

Authors:  Jo-Anne H van Burik; Roberta S Hare; Howard F Solomon; Michael L Corrado; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2006-02-21       Impact factor: 9.079

10.  Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles.

Authors:  Andrew S Chau; Cara A Mendrick; Frank J Sabatelli; David Loebenberg; Paul M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191
View more
  9 in total

1.  X-ray structure of 4,4'-dihydroxybenzophenone mimicking sterol substrate in the active site of sterol 14alpha-demethylase (CYP51).

Authors:  Ali Nasser Eddine; Jens P von Kries; Mikhail V Podust; Thulasi Warrier; Stefan H E Kaufmann; Larissa M Podust
Journal:  J Biol Chem       Date:  2008-03-26       Impact factor: 5.157

Review 2.  Pharmacokinetic/pharmacodynamic profile of posaconazole.

Authors:  Yanjun Li; Ursula Theuretzbacher; Cornelius J Clancy; M Hong Nguyen; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

3.  Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole.

Authors:  Chiung-Kuang Chen; Siegfried S F Leung; Christophe Guilbert; Matthew P Jacobson; James H McKerrow; Larissa M Podust
Journal:  PLoS Negl Trop Dis       Date:  2010-04-06

4.  Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.

Authors:  Russell E Lewis; Nathaniel D Albert; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

5.  Molecular Confirmation of the Linkage between the Rhizopus oryzae CYP51A Gene Coding Region and Its Intrinsic Voriconazole and Fluconazole Resistance.

Authors:  Daiana Macedo; Florencia Leonardelli; Catiana Dudiuk; Laura Theill; Matías S Cabeza; Soledad Gamarra; Guillermo Garcia-Effron
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

Review 6.  Roles for Structural Biology in the Discovery of Drugs and Agrochemicals Targeting Sterol 14α-Demethylases.

Authors:  Brian C Monk; Mikhail V Keniya
Journal:  J Fungi (Basel)       Date:  2021-01-20

Review 7.  Recent Advances and Future Directions in the Understanding of Mucormycosis.

Authors:  Victoriano Garre
Journal:  Front Cell Infect Microbiol       Date:  2022-02-24       Impact factor: 5.293

8.  In vitro Activity of Isavuconazole and Comparators Against Clinical Isolates of Molds from a Multicenter Study in China.

Authors:  Ran Jing; Ian Morrissey; Meng Xiao; Tian-Shu Sun; Ge Zhang; Wei Kang; Da-Wen Guo; Jalal A Aram; Jeffrey Wang; Eric A Utt; Yao Wang; Ying-Chun Xu
Journal:  Infect Drug Resist       Date:  2022-04-22       Impact factor: 4.177

9.  Intrinsic short-tailed azole resistance in mucormycetes is due to an evolutionary conserved aminoacid substitution of the lanosterol 14α-demethylase.

Authors:  Rita Caramalho; Joel D A Tyndall; Brian C Monk; Thomas Larentis; Cornelia Lass-Flörl; Michaela Lackner
Journal:  Sci Rep       Date:  2017-11-21       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.